News
Johnson & Johnson’s HNSCC Therapy Receives FDA Priority Review
Johnson & Johnson’s RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) is currently approved in more than 40 countries, including the US, Europe and Japan, for the subcutaneous treatment of non-small cell lung cancer.
imphoenix82
- July 31, 2026
- 0 Comments
- 14 Views
-
